MicroPort Scientific Corporation

2023 Interim Results

August 2023

MicroPort 微创

Disclaimer

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

FORWARD-LOOKING STATEMENTS

Some information contained in this presentation contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe”, “intend”, “expect”, "anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China and other countries that MicroPort operates in.

CONFIDENTIALITY

This presentation is confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.

Contents

Ambitious pursuit of innovation for 25 consecutive years

Core Business

Total cardio solutions

Other sectors covering main clinical specialties

Partnerships with global leading KOLs and MedTech firms

Unswervingly invested in R&D for 25 years

MicroPort微创

Global leading
medical devices company

Uncompromising in quality and relentless pursuit of excellence

Industry leading commercialization capabilities

Building a super-conglomerate of people centric enterprises of
EMERGING MEDICAL TECHNOLOGIES

Outstanding performance across all business segments

1H23 Highlights



Newly obtained registration approvals 25 NMPA[2] 12 FDA 8 CE

30 **NMPA Green Path products**
-**No.1** in industry for **8** consecutive years

Note: 1. Others incl. Medical Imaging, Urinary, Gynecological, Digestive & Respiratory etc.; 2. Refers to NMPA III certificates (initial); 3. Data as of Aug-31, 2023.
*Revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies

Distinguished business highlights and R&D achievements

Total-cardio solutions

Business highlights[1]

R&D achievements

	Business highlights[1]	R&D achievements
Cardio-vascular	• Global sales ↑**42.4%** YOY, achieved remarkable growth of accessories • Non-China revenue ↑**93.7%** YOY (Asia Pacific ↑**142%**, South America ↑**125%**), sales and distribution channel covered **73** countries/ regions	• **InterLumos™** Microcatheter & **AncherV™** Anchor Balloon obtained **NMPA approval**, • Guide Catheter & Double Lumen Micro-Catheter **submitted** for NMPA • **Firesorb® submitted** for NMPA review • Completed clinical enrollment of **Rotational Atherectomy System & Intravascular Lithotripsy Balloon**
CRM	• China revenue ↑50.5% YOY, robust sales growth of 1st MRI domestic pacemaker • Non-China 2.3% YOY (EEMEA ↑ 73%, AP ↑ 63%), rapid growth of Bluetooth® pacemakers (↑ 49% YOY) and ICDs (↑ 13% YOY)	• Obtained **FDA clearance** for Bluetooth® product series incl. **Alizea™** and **Celea™** • **Ulys™** ICD and **Invicta™** lead approved in **Japan** • **Platinium™** CRT-D obtained **NMPA approval**, • Progressing NMPA registration of **full-body MRI** pacemaker ENO & Vega MRI lead
Heart valve	• Revenue ↑**41.4%** YOY (**implantation↑ ~46%**); GPM **+2** ppts (**66.1%**), significant enhancement seen in operating efficiency • Overseas sales ↑**243.1%** YOY, smoothly progressing **CE registration**	• Progressing FIM study of self-developed TMVR system (**world's 1st** clinical-phase dry-tissue TMVR system), 1st FIM case completed **1yr-follow-up** • **VitaFlow® III** completed **design freeze**, embedded with the **world's 1st** steerable retrievable delivery system, expected **NMPA submission in Q4**
Electro-physiology[3]	• Revenue ↑**16.6%** YOY, net profit ↑**44.6% YOY,** 3D navigation cases ↑**50%+** YOY, • **TOP 1** Chinese player with **40,000+ 3D cases** performed accumulatively	• Green Path products, **IceMagic®** cryoablation system & catheter **obtained NMPA approval** • Actively promoting clinical enrollment for **Force-sensing PFA Catheter**
Endo-vascular	• China ↑**32.0%** YOY (Castor® ↑**32%**, Minos® ↑**45%**, Reewarm® PTX ↑**89%**) • Non-China revenue ↑**114.3%** YOY, innovative products covered **28** overseas markets across EU, South America and Asia	• Four products **submitted for NMPA:** Vflower® & Resuscitative Endovascular Balloon & Fibered Occlusion System & Peripheral PTA Balloon Catheter • Cratos® & Vewatch® **completed enrollment** of registration trial
Neuro-vascular	• Revenue ↑**45.2%** YOY, significant enhancement in operating profit (↑ **505.2%** YOY), turnaround in net profit • **Four** products successfully commercialized in **12** countries/ regions overseas	• **Four NMPA approvals newly obtained** & three products submitted for NMPA • With approval of **Tigertriever®** & **W-track®** , further enhanced AIS product portfolio
Surgical robot	• Revenue ↑**3,110.2%** YOY, **Toumai®** completed **4 commercial installation**, obtained **multiple bidding orders** for in Top-tier hospitals, installation on-track • Completed **1,200+/ 600+** human clinical surgeries for Toumai® / SkyWalker™	• **SkyWalker™** approved in Australia and Brazil • Mona Lisa obtained **NMPA** approval, the **1st** prostate puncture robot approved in China • Over **50** 5G remote surgeries completed, created numerous records of **1st remote surgery in China and globally**
Ortho-pedics	• China ↑ **51.1%**YOY, sales growth outperformed Chinese market (knee procedures ↑ **~100%**, Evolution® medial-pivot knee implantation ↑ **~200%** YOY) • Overseas knee sales ↑ **16%** YOY, growing popularity of Medial Pivot design	• **Three NMPA** approvals, incl. "Green Path" Zirconium-niobium alloy femoral head and Fixed-bearing Unicondylar Knee system • Completed **FDA 510 (k) submission** for Evolution® Hinge knee joint system and Procotyl® P Acetabular Cup
Surgical device	• Revenue ↑ **39.4%** YOY, rapid overseas sales growth of oxygenators • Smoothly promoting hospital entry of Vitasprings™ in China	• **FILAVENT™** femoral cannula series obtained NMPA approval, become the 1st China-developed TPU Femoral Cannula to go to market

Note: 1. All registration numbers refer to NMPA III certificates (incl. change of certificate); 2. Refer to MicroPort® product; 3. Electrophysiology (EP) business under associated company

Rapid business development through geographic diversity

Global Strategic Triangle

EMEA
↑ 9% YOY
Revenue growth

Asia[1]
↑ 38% YOY
Revenue growth

Americas
↑ 12% YOY
Revenue growth

Europe
- Endo: Castor® completed first implantation in **5 EU countries**;
- Neuro: NUMEN® successfully entered **UK** and **3 EU countries**, gain access to French Health Insurance
- Heart valve: smoothly progressing CE registration of **VitaFlow Liberty™**
- Surgical robots: **DFVision®** obtained CE mark, **Toumai ®** submitted for CE review

Middle East
- Cardio: obtained **Top 2** market share of stents volume in **Iran**
- Neuro: NUMEN® newly approved in **Saudi Arabia**

Asia Pacific
- Cardio: DES revenue ↑**142%** YOY, sales ramp up in multi-regions
- CRM: Ulys™ & Invicta™ approved in **Japan**
- Endo: Minos® & Hercules® LP approved in **Singapore**, **3** core products approved in **Thailand**
- Heart valve: VitaFlow Liberty™ & Alwide Plus® approved in **Thailand**

Australia
- Neuro: **NUMEN®** approved
- Surgical robots: **SkyWalker™** obtained market approval

United States
- Cardio: **Firefighter™ NC Pro** PTCA Balloon approved
- CRM: obtained FDA clearance for **Bluetooth product series**, incl. Alizea™ and Celea™
- Surgical robots: continuously promoting **Skywalker™** installation
- Rehabilitation: **TherMotion®** approved
- ART:CryoX Vitrification Freeze Kit & Thaw Kit approved

South America
- Cardio: DES revenue ↑**125%** YOY, achieved **Top 1** market share in **Argentina**
- Endo: **Reewarm®** PTX DCB completed 1st implant in **Brazil**
- Neuro**: U-track®** successfully commercialized in **Brazil**
- Surgical robots: **SkyWalker™** approved in **Brazil**
- Rehabilitation: **TherMotion®** approved **in Columbia**

100+
Countries & regions

20,000+
Hospitals

9,500+[4]
Patents (incl. applications)

Note: 1. incl. China; 2. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies; 3. as of Aug-31, 2023

Contents

Cardiovascular business

Business highlights



#1 China
#2 Global
Market share

China

- **1H23 revenue $63.1mn, up 33.5% YOY**, sales of accessories boost (**+92%** YOY), successfully promoted registration for multiple high-end access products;
- Continuously improving hospital coverage, the DES portfolio had entered **3,300+** hospitals, signifying a **~90%** coverage rate for all PCI-capable hospitals in China;
- Sales volume of Firekingfisher™ **up ~130%** YOY, thanks to increasing recognition for the optimized delivery system by surgeons.

Non-China

- **1H23 revenue $16.1mn, up 93.7% YOY** (Asia Pacific **+142%,** South America **+125%**, EMEA **+21%**), sales channel accumulatively covered 73 countries and regions, market share ramp up in covered area;
- GPM increased by **4 ppts**, thanks to successful maintenance of ASP, higher sales growth of high-end products in the sales mix, and continuous volume increase in ex-bidding market;
- **Firefighter™ NC Pro** PTCA Balloon Catheter obtained market authorization by the FDA.

R&D

- InterLumos™ Micro-Catheter & AncherV™ Anchor Balloon obtained **NMPA approval,** Guide Catheter & Double Lumen Micro-Catheter **submitted** for NMPA;
- Firesorb® released **FUTURE-III** 1-year follow-up results, NMPA registration in progress;
- **"Green Path"** product Coronary Rotational Atherectomy Catheter & Intravascular Lithotripsy Balloon **completed last enrollment**;
- Smoothly progressing clinical enrollment of NSE Balloon & Coronary Covered Stent.

Offers Interventional Cardiology total-solution globally

- **Globalization:** covered **73** countries and regions, multiple products under global registration, **Firehawk®** under 1 yr follow-up before FDA submission
- **Innovation:** consecutive investment in innovation, strategically developed multiple active devices covering complex coronary artery disease

Product pipeline



- Beyond Prefer™ Guide Wire
- InterLumos™ Micro-catheter
- AncherV™ Anchor Balloon
- Guide Catheter
- Double lumen micro-catheter (DLMC)
- Firesorb® Bioresor-bable Scaffold
- Non-slip-element (NSE) balloon
- Coronary Covered Stent
- Coronary Rapamycin Drug-coated Balloon (DCB)
- Coronary Rotational Atherectomy System
- Intravascular Lithotripsy Balloon
- Firehawk® (FDA)
- Pressure Guidewire
- Intra-aortic Balloon Pump (IABP)
- Microvascular-circulation medical device

Products newly approved for marketing

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies

Orthopedics business

Non-China business

Revenue



Breakdown by region



Revenue
EMEA: ↑ 18%

Business overview

- **1H23 revenue $104.2mn, up 7.7% YOY**, strong revenue growth disrupted by supply chain issue since March, significant recovery seen in July;
- Accomplished **~19% growth in volume** as prior year, becoming the highest sales volume ever achieved, despite supply challenges globally;
- Knee sales up **16% YOY**, thanks to the growing popularity of Medial Pivot design, as well as **synergy with SkyWalker™**;
- Completed **FDA 510 (k) submission** for Evolution® Hinge knee joint system and Procotyl® P Acetabular Cup;
- Global manufacturing collaboration in progress, multi-projects in execution.

Collaboration with Medbot

- Continuously promoting Skywalker installation in US hospitals, with 2 units progressing into **final sales stage**, robotics platform has **successfully generated additional implant revenue**;
- Accelerating international installation of Skywalker, 2 units **close to placement** in Europe;
- Showcased “SkyWalker-Medial Pivot” combo in **SRS 2023**, earned widespread recognition from surgeons.

China business

Revenue



Joint products



Business overview

- **1H23 revenue 11.6$mn, up 51.1% YOY**, mainly driven by strong recovery of joint implants, sales growth outperformed Chinese market;
- Knee procedures **close to double**, thanks to significant advantage in quality, gained volume released by global competitors, market share ramp up, Evolution® medial-pivot knee implantation **up ~200%** YOY;
- GPM improved **16 ppts**, mainly attributed to multiple cost-cut measures, especially through global collaboration for imported Evolution® Knee;
- Revenue decline in Spine & Trauma, decrease mainly caused by one-off buyback as well as price drop due to VBP policy.

R&D progress

- Obtained **3 NMPA approvals**, incl. “Green Path” product, Zirconium-niobium alloy femoral head and Fixed-bearing Unicondylar Knee system;
- Continuously release innovative products through the Zirconium-niobium alloy material platform, femoral condyle has submitted for NMPA review;
- Pipeline products covered comprehensive clinical needs, incl. revision knee system, small joints, and biomaterials.

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies

CRM business

Non-China business

Revenue

USD: million



One of the **ONLY 5** multi-national players

Business overview

- **1H23 revenue $100.5mn, up 2.3% YOY**, mainly affected by international tension on the material market, which resulted in shortage of leads supply;
- Substantial sales growth in EEMEA **(+73%** YOY), AP (**+63%** YOY), rapid growth in Bluetooth® pacemakers (**+49%** YOY) and ICDs (+13% YOY);
- Obtained **FDA** clearance for Bluetooth® pacemakers Alizea™ and Celea™ & combined health-management devices, Ulys™ ICD and Invicta™ lead approved in Japan, strengthen access to **high value-added markets**;
- Significant rise in lead manufacturing in 2H, progress already observed.

Product pipeline

- Ulys™/Edis™/Gali™ ICD & CRT-D (CE)
- Invicta™ ICD lead (CE)
- Alizea™/Celea™ Bluetooth® Pacemakers Vega™ pacing leads (FDA)
- ENERGYA/TALENTIA Bluetooth® ICDs & CRT-Ds (CE)
- Left Bundle Branch pacing lead (CE)
- Pulsea™ Bluetooth® CRT-P (CE)
- Leadless pacemaker

China business

Revenue

USD: million



Top 1
Chinese player
No. 1
market share for China-made products

Business overview

- **1H23 revenue $7.8mn, up 50.5% YOY**, mainly attributed to the full-blown recovery of pacemaker implantation surgeries in China;
- Sales of domestic-made pacemakers ramp up (**+107%** YOY), thanks to strong sales growth of **1st** China-made MRI-compatible Rega® pacemaker;
- Smoothly progressing NMPA registration of China-made **full-body** MRI **compatibility** ENO pacemaker & Vega lead;
- Platinium™ CRT-D obtained **NMPA approval**, prepared Invicta™ lead for NMPA submission, China-made SPACE-HP ICD under type testing stage.

Product pipeline

- Platinium™ ICD
- Rega® pacemaker (MRI OOC)
- Platinium™ CRT-D
- ENO™ pacemakers (MRI) Veg lead (MRI)
- BonaFire™ Passive Pacing lead (MRI)
- Space HP ICD
- Invicta™ defibrillation leads

Products newly approved for marketing

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies

Endovascular business

Business highlights

Key Financials



China

- **1H23 revenue $83.0mn, up 32.0% YOY**, sustained competitive edge leverage on robust and innovative product portfolio;
- Strengthening market penetration: Castor®, world's only-in-class thoracic branch stent-graft system, covered **950+** hospitals, Minos® covered **700+** hospitals, Reewarm® PTX covered **750+** hospitals, Talos® & Fontus® entered **200+** hospitals after launched, completed **2,000+** implantation;
- Enhanced investing in innovation: Vflower® Venous Stent System & Resuscitative Endovascular Balloon & Fibered Embolization Coil **submitted for NMPA**, Cratos® Thoracic Endovascular Stent Graft System & Vewatch® Vena Cava Filter **completed enrollment** of registration trial.

Non-China

- **1H23 revenue $6.0mn, up 114.3% YOY**, innovative products covered **28** overseas markets across EU, South America and Asia;
- Castor® (custom-made) entered into **14** countries, Minos® entered into **15** countries, Hercules® Low Profile entered into **16** countries;
- Reewarm® PTX DCB **completed 1st overseas implantation** in Brazil;
- Minos® & Hercules® LP newly approved in Singapore, **3** core products successfully approved in Thailand.

	Product	Pre-clinical	Clinical	Registration
Aortic Intervention	Resuscitative Endovascular Balloon			• Submitted for **NMPA** review
	Cratos® Branched Aortics Stent Graft System			• Follow-up phase of registration trial
	Aegis® II Abdominal Aortic Stent Graft System			• Conducting multi-center clinical trial
	Multi-branched Aortics Stent Graft System			• Follow-up phase of FIM study
Peripheral Intervention	Peripheral PTA Balloon Catheter			• Submitted for **NMPA** review
	Fibered Embolization Coil			• Submitted for **NMPA** review
	Vflower® Venous Stent System			• Submitted for **NMPA** review
	Vewatch® Vena Cava Filter			• Completed enrollment of registration trial
	Fishhawk™ Mechanical Thrombectomy Catheter			• Conducting multi-center clinical trial
Oncological Intervention	TIPS Stent Graft System			• Conducting multi-center clinical trial
	Imiginable Embolic Microspheres			• Kick off clinical enrollment in near term

Product admitted to NMPA Green Path

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies

Neurovascular business

Business highlights



China

- **1H23 revenue $40.5mn, up 46.4% YOY**, with significant enhancement seen in profitability;
- **Market access**: newly entered **200+** hospitals, total coverage reached **2,800+**, wherein "Eagle & Swallows" program entered **100+** hospitals, covered **~700** hospitals in **200+** lower-tier;
- **Product sales**: thanks to continuous market penetration, maintained strong sales growth of Tubridge®; NUMEN® & Bridge® & U-track® gained fast-growing market share; rapid market entry of Neurohawk® & Diveer®;
- **Registration: 4 NMPA approvals & 3 products submitted for NMPA**, further enhanced AIS product portfolio, create integrated and diversified neurovascular disease solution with 17 commercialized products.

Non-China

- International business generated revenue of **$2.1mn**, up 27.3% YOY;
- Four products successfully commercialized in 12 countries/ regions, covering half of the countries ranking top 10 worldwide by volume;
- **NUMEN®** completed 1st commercial implantations in **5** countries, newly approved in 4 countries;
- **U-track®** completed 1st batch of commercial use in Brazil;
- **Tubridge® & Fastrack®** obtained market approval in Argentina.

	Product	Pre-clinical	Clinical	Registration
Hemorrhagic Stroke	Tubridge Plus® Flow-diverting Stent			• Completed enrollment of registration trial
	Comaneci® Embolization Assist Device*			• CE marked & FDA cleared • **FDA Breakthrough Device Designation** • Design validation stage
	Rebridge® Intracranial Visualized Stent			• Design validation stage
	Liquid Embolic Agent			• Design validation stage
ICAD	Intracranial Drug-Coated Balloon Catheter System			• Design validation stage
Acute Ischemic Stroke	Tigertriever® Revascularization Device*			✓ **NMPA approved & CE marked & FDA cleared**
	W-track® Intracranial Aspiration Catheter			✓ **NMPA approved**
	Balloon Guide Catheter			• Submitted for **NMPA** review
	Neurohawk® Stent Thrombectomy Device 2			• Submitted for **NMPA** review
	Tigertriever® 13 Revascular-ization Device*			• FDA cleared • Design validation stage
Accessories	Q-track® Microcatheter			✓ **NMPA approved**
	Veronwire™ Neurovascular Guide Wire			✓ **NMPA approved**
	Distal Protection Device			• Submitted for **NMPA** review

Product admitted to NMPA Green Path * Products we act as exclusive distributor for Rapid Medical

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, 2. HS/ ICAD/ AIS refers to Hemorrhagic Stroke/ intracranial atherosclerotic disease/ Acute Ischemic Stroke, respectively

Heart valve business

Business highlights



China

- **1H23 revenue $24.1mn, up 38.4% YOY**, implantations **up ~46% YOY,** market share rises in top centers, penetrate continues in primary market;
- Gross profit margin maintain improving trend, up **2 ppts** as compared with 1H22, significantly improvement also seen in operation efficiency;
- Successfully entered **~70** centers, hospital coverage reached **500+**, single-center implantation increased by **8 ppts**;
- AccuSniper™ Double Layer Balloon Catheter obtained **NMPA approval**;
- Smoothly progressing FIM study of self-developed TMVR system, **one-year follow-up** shows significant MR reduction with no recurrence, notable improvement of cardiac function, and quality of life;
- VitaFlow® III completed design freeze, expected NMPA submission in Q4.

Non-China

- Strong revenue growth out of China, **up 243.1% YOY**, leverage on strong sales channel of Cardiovascular business, TAVI procurement increased rapidly since launched in South America;
- Successfully entered **60+** hospitals overseas, conducted **100+** commercial implantations accumulatively;
- Accomplished multiple key registration stages of VitaFlow Liberty™ CE registration, expected to be the **1st Chinese TAVI product** with CE mark

	Product	Pre-clinical	Clinical	Registration
TAVI	VitaFlow Liberty®			• Approaching **CE** registration
	VitaFlow® III			• Approaching Design freeze
	VitaFlow® Novo Generation			• Design stage
	VitaFlow® Balloon Expandable			• Animal studies
Access	AccuSniper™ Double Layer Balloon Catheter			✓ **NMPA approved**
	Expandable Sheath			• Design stage
TMV	Self-developed replacement product		• **Progressing FIM studies**	
	Self-developed edge to edge repair product		• Animal studies	
	AltaValve™ - replacement product		• **Approaching EFS Completion**	
	Amend™ - repair product		• **Progressing EFS**	
TTV	Self-developed replacement product		• Design Stage	
	Self-developed edge to edge repair product		• Design stage	
	Replacement product - partnership with 4C		• Design stage	

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact.

Surgical robot business

Business highlights

Business overview

- **1H23 revenue $4.9mn, up 3,110.2% YOY**, recorded robust sales growth for all marketed products, achieved breakthrough in globalization;
- Toumai® maintain **leading position**, market share rises simultaneously, completed **4** commercial installations, and won bids in top-tier hospitals;
- Cumulatively completed **1,200+** human clinical surgeries for Toumai®, and **600+** robot-assisted clinical validation surgeries for SkyWalker™.

Research & Development

Clinical developments

Laparoscopic: Toumai® Single-arm kick-off enrollment for registration trial;

Orthopedics: SkyWalker™ entry into clinical evaluation stage for Total Hip Arthroplasty and Unicompartmental Arthroplasty;

Percutaneous: Mona Lisa obtained **NMPA** approval, become the 1st prostate puncture robot obtained the approval in the field of urology in China;

Panvascular: progressing registration for R-ONE, to obtain NMPA in 2023;

Natural orifice: conducting clinical trial for Trans-bronchial Surgical Robot.

5G remote surgeries

- Over **50** 5G remote surgeries completed by surgical robots portfolio; created numerous records of **1st remote surgery in China and globally**;
- R-ONE successfully completed **China's 1st** robot-assisted 5G ultra-remote PCI surgery crossing a distance of 2,800 kilometers in July.

Globalization

Overseas registration

- DFVision® obtained CE mark;
- SkyWalker™ obtained market approval in Brazil and Australia;
- Toumai® submitted application for the CE mark.

Commercialization

- Thanks to strong synergy with Medial-Pivot Knee, SkyWalker™ rapidly deploying installation and commercialization in the US, actively exploring market opportunities worldwide.

	Product	Pre-clinical	Clinical	Registration
Laparoscopic	Toumai® Laparoscopic Surgical Robot *("Toumai®")* 			✓ **Obtained NMPA** • CE marking in progress
Laparoscopic	Toumai® 2nd Generation 			• Submitted for NMPA review
Laparoscopic	Toumai® Single-arm Laparoscopic Surgical Robot			• Started enrollment of registrational trial
Orthopedic	Skywalker™ Orthopedic Surgical Robot 			✓ **Obtained NMPA approval** ✓ **Obtained FDA & CE & ANVISA & TGA approval**
Orthopedic	Spine Surgical Robot			• Design validation stage
Natural Orifice	Trans-bronchial Surgical Robot			• Started enrollment of registration trial
Panvascular	R-ONE® Vascular Interventional Surgical Robot 			• NMPA registration on progress • Obtained **CE** in 2019
Panvascular	TAVR Surgical Robot			• Design development stage
Percutaneous	iSR'obot™ Mona Lisa Robotic Transperineal Prostate Biopsy System *("Mona Lisa™")* 			✓ **Obtained NMPA approval** • Obtained **CE** & **FDA** in 2017
Percutaneous	Thoracic and Abdominal Puncture Robot			• Design validation stage

Product admitted in NMPA Green Path

Note: 1. for the indication in percutaneous nephrolithotomy

Surgical devices business

Business highlights

Business overview

- Provide **systematic life support solutions for acute critical cases**;
- **1H23 revenue $3.1mn, up 39.4% YOY**, thanks to rapid overseas sales of oxygenators, smoothly promoting hospital entry of Vitasprings™ in China;
- **FILAVENT™** femoral cannula series obtained NMPA approval, become the 1st China-developed TPU Femoral Cannula to go to market.

Product overview

19 **Products** received **NMPA approvals**

9 **Products** received **CE mark**

Flagship – MOBYBOX ECMO System

- **1st fully integrated ECLS system** to provide both blood flow and gas management in a single device, obtained CE mark under MDR regulation;
- Leverage on diversified portable design, aiming to forge **movable critical-care unit** focusing on pre-hospital emergency care.

Globalization

13 **Overseas markets** received product approvals

17 **Countries** with established sales channels

	Product	Pre-clinical	Clinical	Registration
Emergency transport system	Hemovent[1] MOBYBOX® ECMO			✓ Obtained CE mark
	Hemovent[1] MOBYO™ ECMO Oxygenator			✓ Obtained CE mark
	Hemovent[1] WATCHA™ Blood Oxygen Saturation Monitoring Sensor			✓ Obtained CE mark
ECMO	Centrifugal ECMO system	• Approaching Animal studies		
	Double lumen cannula	• Approaching Animal studies		
	Transseptal cannula	• Design stage		
CPB	Vitasprings™ Membrane Oxygenator			✓ Obtained NMPA approval
	Cannula series			✓ Obtained NMPA approval & CE mark
	FILAVENT™ Femoral Cannula series			✓ Obtained NMPA approval
	MOBYO™ ECMO Oxygenator	• Animal studies		
Congenital heart diseases	Atrial Septal Defect Occluder			✓ Obtained NMPA approval
	Patent Ductus Arteriosus Occluder			✓ Obtained NMPA approval
	Ventricular Septal Defect Occluder			✓ Obtained NMPA approval
	Occluder delivery system			✓ Obtained NMPA approval
Others	Patient monitoring system	Data processing platform	ICU management	Heart failure / In-hospital transport system

Product admitted in NMPA Green Path

Note: 1. Hemovent, a German ECLS company was fully acquired by MicroPort in Oct 2021

Emerging business - medical imaging

Business highlights

Business highlight

- Provide **total precise interventional imaging solution**, multifaceted coverage including panvascular (cardiovascular, neurovascular, and peripheral vascular), structural heart/EP, metabolism and etc.
- **1H23 revenue up 298.0% YOY**, maintained sales growth of **1st** fully sealed purge-free catheter Argus NOPURGE™ (OCT catheter)
- Processed **1st** installation of Soul-Man™ DSA System
- ArgusClarity™ obtained market approval in **Singapore**;
- Self-developed IVUS imaging system & accompanying disposable catheter commenced type examination.

Flagship products

ArgusClarity™ OCT system & NOPURGE™ catheter

- Decreases the amount of contrast agent used
- Reduces the operation steps and time

Soul-Man™ DSA System

- Low dose acquisitions
- Compact design
- Intelligent human-machine interactions
- High resolution images

	Product	Indication	Pre-clinical	Clinical	Registration
OCT	Insight-100 ArgusClarity™	PCI			✓ Obtained NMPA approval
OCT	Insight-100–1350 NOPURGE™ (OCT catheter)	PCI			✓ Obtained NMPA approval
OCT	Insight-100h High Speed OCT	PCI			✓ Obtained NMPA approval
OCT	High Resolution OCT	PCI		• Type testing stage	
OCT	Peripheral/Intracranial OCT	Panvascular			
DSA	Soul-Man™ DSA System	Interventional			✓ Obtained NMPA approval
IVUS	Coronary Artery IVUS	PCI		• Type testing stage	
IVUS	Peripheral/Intracranial IVUS	Panvascular			
IVUS	IVUS-ICE	SHD			
Multi-module interventional	OCT+IVUS	PCI		• Prototype development stage	
Multi-module interventional	OCT+IVUS+FFR	PCI			
MRI	Imported MRI System	Prostate biopsy			✓ Obtained FDA approval
MRI	Chinese MRI System	Prostate biopsy			

Product admitted in NMPA Green Path

Emerging business - urinary, gynecological, digestive & respiratory

Business highlights

- Provide innovative total solutions in endoscope and disposal devices to **urological, gastrointestinal, gynaecological & respiratory** diseases;
- **1H23 revenue up 190.0% YOY**, formed total-solution for Urinary Calculus
- **20 NMPA** certificates & **3 CE** marks obtained accumulatively;
- Milestone progress obtained under the development of endoscopic imaging pipeline in digestive endoscope;
- Closed strategic financing with RMB 140mn raised.

R&D progress

30+ **Product candidates** in pipeline

1 Products obtained **NMPA Green Path**

Key product – 1st in China, 2nd globally

- Smoothly progressing registration trial for "Green Path" product, Prostatic urethral lift system

Globalization

6 **Products** successfully commercialized in 4 countries/ regions

3 **Products** obtained CE mark in 2023

	Product	Indication	Pre-clinical	Clinical	Registration
Single-use endoscope	Single-use digital ureteroscope catheter	Urology	✓ Obtained NMPA approval		
	Single-use digital choledochoscope catheter	Gastroenterology	✓ Obtained NMPA approval		
	7 other candidates covering urological, gastrointestinal, gynecological and respiratory indications				
Reusable endoscope	**3** candidates covering gastrointestinal and respiratory indications				
Passive consumables	Nephrostomy balloon dilation catheter	Urology	✓ Obtained NMPA approval		
	Single-use endoscopic retrieval basket (3 claws)		✓ Obtained NMPA & CE approval		
	Ureteral access sheath		✓ Obtained NMPA approval		
	Single-use urinary track guidewire		✓ Obtained NMPA & CE approval		
	Ureter balloon dilation catheter		✓ Obtained NMPA & CE approval		
	Prostatic urethral lift system		✓ Progressing registration trial		
	Hybrid zebra guidewire				
	Ultrathin basket				
	Ruyi Clip™ soft tissue clip	Gastroenterology	✓ Obtained NMPA approval		
	6 other candidates covering gastrointestinal and urological indications				
Energy-based	**5** candidates covering general, gynecological and gastrointestinal indications				
Neuro modulation	**3** candidates covering urological and respiratory indications				

Product admitted in NMPA Green Path

Emerging business

Business highlights

- **1H23 revenue increased by 16.6% YOY**, net profit **up 44.6% YOY**
- 3D navigation cases up **50%+ YOY**, maintained **TOP 1** Chinese player with **40,000+** 3D cases performed accumulatively
- Total hospital coverage reached **900+**, 3D products covered **700+** hospitals, TrueForce® entered **100+** hospitals after successfully launched in February 2023
- **Green Pat**h products, IceMagic® Cryoablation System & Catheter obtained **NMPA** approval, become the **1st** China-develop cryoablation system approved

Globalization

- One of the few global players with **all-around EP solutions**
- Products entered **31** overseas countries and regions
- **20 CE** marks & **4 FDA** clearance obtained accumulatively
- Core product TrueForce® submitted for **CE**

Sports medicine

- Built integrated product pipeline covering implants, surgical tools, and innovative active devices in sports medicine;
- Completed **full-coverage** of conventional portfolio, **8** NMPA approvals and **2** FDA clearance obtained in 1H23;
- Smoothly progressing registration of key innovative projects, Ligatube® received NMPA approval in Aug, become the **1st** China-developed Tunnel-form Rotator Cuff Repair system;
- Processing bidding for **Galaxy Insight™** 4K high-resolution arthroscope system & **Endosharp®** high-speed surgical power system in 10+ hospitals;
- **World's 1st** long-term implantable rotator cuff spacer system, Archimedes® completed 6-month follow-up of registration trial in China, smoothly progressing CE marking process.

EverPace[1]

竞捷医疗 ENDOPHIX[1]



Rehabilitation

- Provide total solutions for rehabilitation medical services, mainly focusing on rehabilitation equipment covering musculoskeletal and neurological rehabilitation
- TherMotion®, Cryo-thermo compression device successfully **commercialized** in China, completed coverage of 100+ hospital, sales channel covered main top-tier cities in China;
- TherMotion® gained market approval in the **US and Columbia**
- REBRAIN® lower limb rehabilitative training robot entered massive production stage
- Suzhou rehabilitation clinic officially launched for commercial operation

Blood glucose, tumor chemotherapy delivery & pain management[1]

- Sales of **La Fenice®** insulin pumps ramp up, thanks to continued increase in repurchase rate
- 2nd generation insulin pump obtained market approval
- Completed type testing for CGM, kick-off clinical development in near term\
- AutoEx® portable electric infusion pump obtained **NMPA**

Assisted reproductive technology (ART) [1]

- Provide total-solutions covering entire cycle of ART
- **3 NMPA** & **2 FDA** clearance newly obtained
- Conducted strategic development of Foods for Special Medical Purpose ("SMP foods")

MicroPort微创 Note: 1. refers to business sectors under associated company

Contents

Consolidated Financial Performance

Revenue

USD: million



Gross profit margin

Operating expenses

USD: million



Total net loss & net loss attributable to equity shareholders

USD: million



Note: revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies

Operating Expenses

Sales & marketing expenses

USD: million



Sales & marketing expenses increased by 15.8%YOY

- Increase in marketing activities and product promotion

Administrative expenses

USD: million



Administrative expenses decreased by 28.0%YOY

- Due to the Group's effective cost control and scale of operations.

R&D expenses

USD: million



R&D expenses remain flatYOY

- The proportion of research and development costs to revenue decreased due to execution of cost controls

Contents

Innovative product pipeline fueling long-term growth

Cardio-vascular	**Guide Catheter** *NMPA*	**Firesorb® Bioresorbable Scaffolds** *NMPA* 	**Non-slip-element Balloon** *NMPA*	**Coronary Covered Stent** *NMPA*	**Coronary Rapamycin Drug-coated Balloon** *NMPA*	**Coronary Stent Graft System** *NMPA*	**Coronary Rotational Atherectomy System** *NMPA* 	**Intravascular Lithotripsy Balloon** *NMPA* 	**Firehawk® stent** *FDA*	**Pressure Guidewire** *NMPA*
Orthopedics	**Classic Profemur® Cemented XM® Femoral Stem** *FDA*		**Hinged Knee Joint System** *FDA*		**Evolution Tibia Cones** *FDA* 		**2D-to-3D Imaging Technology** *FDA* 	**Wrist Joint Prosthesis System** *NMPA*	**Procotyl P Acetabular Cup (Dual Mobility/ Revision)** *FDA*	
CRM	**ENO™ Pacemaker (MRI)** *NMPA* 	**BonaFire™ Passive Lead (MRI)** *NMPA* 	**ENERGYA/TALENTIA Bluetooth® ICD/CRT-D** *CE* 	**Left Bundle Branch pacing lead** *CE* 	**Pulsea™ Bluetooth® CRT-P** *CE* 		**Space HP ICD/CRT-D** *NMPA* 	**Invicta™ ICD Lead** *NMPA*	**Leadless Pacemaker** *NMPA&CE* 	
Endo-vascular	**Resuscitative Endovascular Balloon** *NMPA*	**Vflower® Venous Stent System** *NMPA* 	**Peripheral PTA Balloon Catheter** *NMPA*	**Fibered Embolization Coil** *NMPA*	Vewatch® **Vena Cava Filter** *NMPA*	**Fishhawk™ Catheter** *NMPA*	**Cratos Branched Aortics Stent Graft System** *NMPA*	**Aegis® II Abdominal Aortic Stent Graft System** *NMPA*	**TIPS Stent Graft System** *NMPA*	
Neuro-vascular	**Comaneci® Embolization Assist Device** *NMPA*	**Balloon Protection Guide Catheter** *NMPA*	**Neurohawk® Stent Thrombectomy Device 2** *NMPA*		**Tubridge Plus® Flow-diverting Stent** *NMPA*	**Tigertriever® 13 Revascular-ization Device*** *NMPA*	**Rebridge® Intracranial Visualized Stent** *NMPA*	**Intracranial Drug-Coated Balloon Catheter System** *NMPA*	**Liquid Embolic Agent** *NMPA*	
Heart Valve	**VitaFlow Liberty®** *CE*	**VitaFlow® III** *NMPA*	**VitaFlow™ Novo Generation** *NMPA*	**VitaFlow® Balloon Expandable** *NMPA*	**Expandable Sheath** *NMPA*	**Self-developed TMVR product** *NMPA*	**AltaValve™ TMVR Product *NMPA*** 	**Amend™ TMVr Product NMPA** 	**Self-developed edge to edge repair product NMPA**	**TTV** **Self-developed replacement product/ Self-developed edge to edge repair/ Trivid**
Surgical Robot	**R-ONE® Panvascular Surgical Robot** *NMPA* 		**Skywalker™ Orthopedic Surgical Robot (Hip)** NMPA 		**Toumai® Laparoscopic Surgical Robot** *CE* 		**Toumai® Single-arm Laparoscopic Surgical Robot** *NMPA*	**Trans-bronchial Surgical Robot** *NMPA*	**TAVR Surgical Robot** *NMPA*	**Spine Surgical Robot** *NMPA*
Surgical Devices	**Arterial Micro-Embolic Filter (new type)** *NMPA*		**Double lumen cannula** *NMPA*		**MOBYBOX System** *NMPA* 		**Centrifuge ECMO** *NMPA* 	**Transseptal cannula** *NMPA*		
Electro-physiology[1]	**Columbus™ 3D EP Navigation System V4** *NMPA*		**Flashpoint® Renal Artery Ablation Catheter** *NMPA*		**Renal RF Ablation System** *NMPA*		**Force-Sensing Pulse Field Ablation Catheter** *NMPA*			

Note: 1. Electrophysiology business under associated company

Contents

Appendix I - Consolidated Income Statement

USD'000	2023 1H	2022 1H	Var.
Revenue	482,605	404,984	19.2%
Cost of sales	(194,189)	(157,282)	23.5%
Gross profit	**288,416**	**247,702**	**16.4%**
Other net income	17,039	41,356	-58.8%
Research and development costs	(187,334)	(186,430)	0.5%
Distribution cost	(169,800)	(146,610)	15.8%
Administrative expenses	(95,890)	(133,259)	-28.0%
Other operating costs	(12,374)	(8,328)	48.6%
Loss from operations	**(159,943)**	**(185,569)**	**-13.8%**
Finance cost	(37,256)	(46,050)	-19.1%
Gain on deemed disposal of a subsidiary	2,845	-	N/A
Gain on deemed disposal of interest in equity-accounted investees	5,437	1,920	183.2%
Share of losses of equity-accounted investees	(17,258)	(18,141)	-4.9%
Loss before taxation	**(206,175)**	**(247,840)**	**-16.8%**
Income tax	(13,746)	(5,435)	152.9%
Loss for the period	**(219,921)**	**(253,275)**	**-13.2%**
Attributable to: Equity shareholders of the Company	**(162,618)**	**(198,130)**	**-17.9%**

Appendix II - Consolidated Balance Sheet

USD'000	30 June 2023	31 Dec 2022	Var.
Non-current assets			
Investment properties	6,315	6,579	-4%
Other property, plant and equipment	969,558	993,014	-2%
Intangible assets	223,215	223,683	0%
Goodwill	265,571	262,829	1%
Equity-accounted investees	407,214	423,873	-4%
Other financial assets	19,676	23,155	-15%
Deferred tax assets	27,893	27,637	1%
Other non-current assets	97,710	94,081	4%
Total non-current assets	**2,017,152**	**2,054,851**	**-2%**
Current assets			
Inventories	395,404	352,428	12%
Trade and other receivables	312,704	284,833	10%
Pledged deposits and time deposits	226,874	60,765	273%
Cash and cash equivalents	843,430	1,203,007	-30%
Derivative financial assets	36,874	38,201	-3%
Total current assets	**1,815,286**	**1,939,234**	**-6%**
Current liabilities			
Trade and other payables	367,557	380,554	-3%
Contract liabilities	24,146	22,598	7%
Lease liabilities	42,457	51,944	-18%
Interest-bearing borrowings	257,366	185,387	39%
Income tax payable	8,217	17,470	-53%
Convertible bonds	650,589	-	N/A
Derivative financial liabilities	5,755	4,172	38%
Total current liabilities	**1,356,087**	**662,125**	**105%**
Net current assets	**459,199**	**1,277,109**	**-64%**

Appendix II - Consolidated Balance Sheet

USD'000	30 June 2023	31 Dec 2022	Var.
Non-current liablities			
Interest-bearing borrowings	417,298	336,689	24%
Lease liabilities	103,828	124,373	-17%
Deferred income	34,068	38,123	-11%
Convertible bonds	98,083	769,553	-87%
Contract liabilities	24,721	24,839	0%
Other payables	233,392	220,997	6%
Deferred tax liabilities	24,305	24,718	-2%
Total non-current liablities	**935,695**	**1,539,292**	**-39%**
CAPITAL AND RESERVE			
Share capital	18	18	-
Reserves	960,178	1,135,012	-15%
Total equity attributable to equity shareholders of the Company	**960,196**	**1,135,030**	**-15%**
Non-controlling interests	580,460	657,638	-12%
Total equity	**1,540,656**	**1,792,668**	**-14%**

Disclaimer

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

FORWARD-LOOKING STATEMENTS

Some information contained in this presentation contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe”, “intend”, “expect”, "anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China and other countries that MicroPort operates in.

CONFIDENTIALITY

This presentation is confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.